Organization | Lebanese University

Lebanese University Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial

2018

NCT04071574

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Lebanese University

Active Ingredients

Drugs in Phase 1 Trials (6)

lopinavir (Kaletra) (1 trial)

palbociclib (ibrance) (1 trial)

remdesivir (Veklury) (1 trial)

ritonavir (Norvir) (1 trial)

rivaroxaban (xarelto) (1 trial)

tocilizumab (actemra) (1 trial)

Drugs in Other Trials (2)

human choriogonadotropin alfa (hCG) (1 trial)

triptorelin (Trelstar) (1 trial)

Indications

Overview

Highest Phase: Phase 1
# of Trials: 3
# of Trial APIs: 8